Oncology and Hematology News and Journal Articles
Exhaled breath temperature higher than 34 degrees Celsius (93.2 degrees F) could serve as a cutoff value to help diagnose lung cancer, according to a new study.
In the field of oncology, we are fortunate to possess a vast and ever-expanding trove of knowledge, and we now have a sufficient foundation of knowledge in many cancers to afford ourselves the luxury of striving to seek wisdom as well.
A recent study has confirmed that TERT promoter mutations are common genetic mutations in cutaneous melanoma, mutations that may be linked with poor prognosis.
Aggressive variants of prostate cancer often take the form of neuroendocrine or small-cell carcinomas, which frequently lack androgen receptor expression and respond poorly to hormonal therapies.
Ultimately, while further follow-up will be enlightening, we believe that there is sufficient evidence now from the primary analysis of CHAARTED to justify the combination of docetaxel and androgen deprivation therapy in all men with metastatic hormone-sensitive prostate cancer.
Meta-analyses of patients with low-volume metastatic hormone-sensitive prostate cancer will likely be required to attain sufficient power to address the role of docetaxel in this setting.
Overall, approximately 2% of patients with bladder cancer will experience a venous thromboembolism event, a rate five times higher than that in the overall population; also, such an event results in a threefold increased risk of death in patients with cancer.
In this interview we discuss a bovine infectious agent, which may interact with carcinogens that arise during cooking or curing, and play a causative role in certain cancer.
Josh Kremer, MD, vice president of clinical development at Eisai, Inc, discusses results of the phase III SELECT trial, which studied lenvatinib in radioiodine-refractory differentiated thyroid cancer.
In this video, Dr. Sledge discusses what the negative results of the ALTTO trial mean for women with HER2-positive breast cancer.
Dr. Katz describes how he uses social media to learn more about patient perceptions of cancer, how to decide which social media to use, and drawbacks to using social media in a professional capacity.
In this interview we discuss the use of newly approved agents for chronic lymphocytic leukemia, next-generation therapies in the pipeline, and how the treatment of this type of leukemia has changed.
As part of our coverage of the 2014 ESMO meeting we discuss recent advances in the treatment of kidney, bladder, and testicular cancers.
In this interview we discuss the American Society of Clinical Oncology’s (ASCO) health information and patient record initiative called CancerLinQ.
As part of our coverage of the ASCO Breast Cancer Symposium we discuss the clinical meaningfulness of pathologic complete response as a surrogate endpoint in breast cancer clinical trials.